Diagnostic method
    31.
    发明授权
    Diagnostic method 有权
    诊断方法

    公开(公告)号:US09371566B2

    公开(公告)日:2016-06-21

    申请号:US11861809

    申请日:2007-09-26

    CPC classification number: C12Q1/6886 C12Q2600/118 C12Q2600/154

    Abstract: The present invention concerns a method for the detection or monitoring of cancer using a biological sample selected from blood, plasma, serum, saliva, urine from an individual, said method comprising: (a) obtaining DNA from the said biological sample; (b) digesting the DNA sample with one or more methylation-sensitive restriction enzymes; (c) quantifying or detecting a DNA sequence of interest after step (b), wherein the target sequence of interest contains at least two methylation-sensitive restriction enzyme recognition sites; and (d) comparing the level of the DNA sequence from the individual to a normal standard, to detect, prognosticate or monitor cancer.

    Abstract translation: 本发明涉及使用选自血液,血浆,血清,唾液,个体尿液的生物样品检测或监测癌症的方法,所述方法包括:(a)从所述生物样品中获得DNA; (b)用一种或多种甲基化敏感性限制酶消化DNA样品; (c)在步骤(b)之后量化或检测目标DNA序列,其中所述靶序列含有至少两个甲基化敏感性限制酶识别位点; 和(d)将来自个体的DNA序列的水平与正常标准进行比较,以检测,预测或监测癌症。

    Diagnostic Method
    33.
    发明申请
    Diagnostic Method 有权
    诊断方法

    公开(公告)号:US20080081338A1

    公开(公告)日:2008-04-03

    申请号:US11861809

    申请日:2007-09-26

    CPC classification number: C12Q1/6886 C12Q2600/118 C12Q2600/154

    Abstract: The present invention concerns a method for the detection or monitoring of cancer using a biological sample selected from blood, plasma, serum, saliva, urine from an individual, said method comprising: (a) obtaining DNA from the said biological sample; (b) digesting the DNA sample with one or more methylation-sensitive restriction enzymes; (c) quantifying or detecting a DNA sequence of interest after step (b), wherein the target sequence of interest contains at least two methylation-sensitive restriction enzyme recognition sites; and (d) comparing the level of the DNA sequence from the individual to a normal standard, to detect, prognosticate or monitor cancer.

    Abstract translation: 本发明涉及使用选自血液,血浆,血清,唾液,个体尿液的生物样品检测或监测癌症的方法,所述方法包括:(a)从所述生物样品中获得DNA; (b)用一种或多种甲基化敏感性限制酶消化DNA样品; (c)在步骤(b)之后量化或检测目标DNA序列,其中所述靶序列含有至少两个甲基化敏感性限制酶识别位点; 和(d)将来自个体的DNA序列的水平与正常标准进行比较,以检测,预测或监测癌症。

    Haplotype analysis
    34.
    发明申请
    Haplotype analysis 有权
    单倍型分析

    公开(公告)号:US20070122805A1

    公开(公告)日:2007-05-31

    申请号:US10542043

    申请日:2004-01-16

    Abstract: The present invention provides an efficient way for high throughput haplotype analysis. Several polymorphic nucleic add markers, such as SNPs, can be simultaneously and reliably determined through multiplex PCR of single nucleic acid molecules in several parallel single molecule dilutions and the consequent statistical analysis of the results from these parallel single molecule multiplex PCR reactions results in reliable determination of haplotypes present in the subject. The nucleic acid markers can be of any distance to each other on the chromosome. In addition, an approach wherein overlapping DNA markers are analyzed can be used to link smaller haplotypes into larger haplotypes. Consequently, the invention provides a powerful new tool for diagnostic haplotyping and identifying novel haplotypes.

    Abstract translation: 本发明提供了高通量单倍型分析的有效方法。 可以通过多个平行的单分子稀释物中的单个核酸分子的多重PCR同时且可靠地测定几种多态性核酸添加标记,例如SNP,并且随后对这些平行单分子多重PCR反应的结果的统计分析导致可靠的测定 的单倍体存在于受试者。 核酸标记在染色体上可以彼此有任何距离。 此外,分析重叠的DNA标记物的方法可用于将较小的单倍型连接到较大的单元型中。 因此,本发明为诊断单倍型和鉴定新型单体型提供了强大的新工具。

    Marker for prenatal diagnosis and monitoring
    36.
    发明申请
    Marker for prenatal diagnosis and monitoring 有权
    产前诊断和监测的标记

    公开(公告)号:US20060019278A1

    公开(公告)日:2006-01-26

    申请号:US11144951

    申请日:2005-06-03

    Abstract: The present invention relates to new methods for diagnosing a pregnancy-associated disorder by analyzing fetal DNA present in the mother's blood. More specifically, this invention relies on the discovery that the maspin gene is differentially methylated in fetal DNA and in maternal DNA and provides these new diagnostic methods, which distinguish fetal DNA from maternal DNA and detect prenatal disorders based on abnormalities in fetal DNA level and methylation status.

    Abstract translation: 本发明涉及通过分析存在于母亲血液中的胎儿DNA来诊断妊娠相关疾病的新方法。 更具体地说,本发明依赖于maspin基因在胎儿DNA和母体DNA中差异甲基化的发现,并提供了这些新的诊断方法,其将胎儿DNA与母体DNA区分开,并根据胎儿DNA水平和甲基化异常检测产前疾病 状态。

    Fetal methylation markers
    39.
    发明申请
    Fetal methylation markers 有权
    胎儿甲基化标记

    公开(公告)号:US20090155776A1

    公开(公告)日:2009-06-18

    申请号:US11784501

    申请日:2007-04-06

    Abstract: This application describes the discovery that, in a pregnant woman, certain genes (such as RASSF1A, APC, CASP8, RARB, SCGB3A1, DAB2IP, PTPN6, THY1, TMEFF2, and PYCARD) originated from a fetus are highly methylated, whereas the same genes of maternal origin are unmethylated. This discovery allows the easy detection of one or more of these methylated fetal genes in a biological sample from a pregnant woman, serving as a universal indicator of the presence of fetal DNA in the sample. These fetal methylation markers are particularly useful as positive controls for a non-invasive analytical process during which the quality and quantity of fetal DNA are monitored. These newly identified fetal markers can also be measured directly for diagnosis of certain pregnancy-related conditions.

    Abstract translation: 该应用描述了在孕妇中发现来自胎儿的某些基因(如RASSF1A,APC,CASP8,RARB,SCGB3A1,DAB2IP,PTPN6,THY1,TMEFF2和PYCARD)高度甲基化,而相同的基因 产妇来源是未甲基化。 该发现允许从孕妇的生物样品中容易地检测这些甲基化胎儿基因中的一种或多种,​​作为样品中胎儿DNA存在的通用指标。 这些胎儿甲基化标记物作为非侵入性分析过程的阳性对照特别有用,在此过程中监测胎儿DNA的质量和数量。 这些新确定的胎儿标记物也可以直接测量以诊断某些妊娠相关病症。

    Solid catalyst component for polymerization of olefins, catalyst comprising the same and use thereof

    公开(公告)号:US07388061B2

    公开(公告)日:2008-06-17

    申请号:US10503515

    申请日:2003-01-30

    Abstract: The present invention provides a solid catalyst component for the polymerization of olefins, comprising magnesium, titanium, a halogen and an electron donor, wherein said electron donor comprises at least one selected from the group consisting of ester of polyol of the formula (I): R1CO—O—CR3R4—A—CR5R6—O—CO—R2  (I) wherein, R1 and R2 groups, which may be identical or different, can be substituted or unsubstituted hydrocarbyl having 1 to 20 carbon atoms, R3-R6 groups, which may be identical or different, can be selected from the group consisting of hydrogen, halogen or substituted or unsubstituted hydrocarbyl having 1 to 20 carbon atoms, R1-R6 groups optionally contain one or more hetero-atoms replacing carbon, hydrogen atom or the both, said hetero-atom is selected from the group consisting of nitrogen, oxygen, sulfur, silicon, phosphorus and halogen atom, two or more of R3-R6 groups can be linked to form saturated or unsaturated monocyclic or polycyclic ring A is a single bond or bivalent linking group with chain length between two free radicals being 1-10 atoms, wherein said bivalent linking group is selected from the group consisting of aliphatic, alicyclic and aromatic bivalent radicals, and can carry C1-C20 linear or branched substituents one or more of carbon atom and/or hydrogen atom on above-mentioned bivalent linking group and substituents can be replaced by a hetero-atom selected from the group consisting of nitrogen, oxygen, sulfur, silicon, phosphorus, and halogen atom, and two or more said substituents on the linking group as well as above-mentioned R3-R6 groups can be linked to form saturated or unsaturated monocyclic or polycyclic ring.

Patent Agency Ranking